Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - antithrombotics - secondary prevention of thromboembolic events  

Related trials

RE-LY 110mg subgroup, 2010 - dabigatran 100mg vs warfarin

FFAACS , 2001 - aspirin vs placebo (on top fluidione)

SIFA, 1997 - Indobufen vs warfarin

EAFT, 1993 - aspirin vs placebo

EAFT, 1993 - oral anticoagulant vs placebo

RE-LY 150mg subgroup, - dabigatran 150mg daily vs warfarin

See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of dabigatran 100mg

    RE-LY 110mg subgroup study, 2010


    Studied treatment dabigatran 110mg daily
    Control treatment warfarin


    Patients patients with a prior stroke or transient ischemic attack

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 2 y
    Remarks sub group ( 20% of the overall study population in RE-LY)

    Remarks / Comments


    Endpoint Studied treat.
    Control treat.
    Graph RR [95% CI]

    thrombo-embolic event (cerebral or systemic)

    NA / -9
    NA / -9
    0,85 [0,59;1,22]

    TE event or ischemic stroke or systemic embolism

    NA / -9
    NA / -9
    0,85 [0,59;1,22]

    Haemmorhagic stroke

    NA / -9
    NA / -9
    0,11 [0,03;0,44]

    intracranial hemorrhage

    NA / -9
    NA / -9
    0,20 [0,08;0,48]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Studied treat. Control treat.
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.


    Trials register # NA
    • 1.Diener HC, Connolly S, Ezekowitz MD, et al.. Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY. American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 195
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend